Anti-PD1 antibodies against the block programmed cell death 1 protein (PD1)/programmed cell death 1 ligand 1 (PD-L1) axis play a major role in inhibiting effector immune cell depletion, leading to impressive advances for treating a variety of advanced malignant neoplasms (3, 4). This evidence concerns the gene PDCD1 and cancer.